Diffuse Large B-Cell Lymphoma (DLBCL)

Cobomarsen    Actively Recruiting for ATLL, CLL and DLBCL in the United States

➤ A Phase 1 clinical trial to test the safety and potential benefits of cobomarsen (MRG-106) for the treatment of patients with cutaneous T-cell lymphoma (CTCL), mycosis fungoides subtype, chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL) and adult T-cell leukemia/lymphoma (ATLL).

Cobomarsen is designed to inhibit a molecule called miR-155 that is commonly found at high levels in certain types of blood cancer, including ATLL, and which may be important for the cancer cells to survive and grow.

This clinical trial is ongoing and recruiting new study participants with CLL, DLBCL or ATLL. Enrollment of patients with CTCL, mycosis fungoides subtype, has been completed for this clinical trial. For information about the SOLAR clinical trial for patients with CTCL, mycosis fungoides subtype, please click here.

More information on this clinical trial can be found here.